SCHEMBL10148196

SCHEMBL10148196

CCN(CC)c1ccc2c(-c3ccc(S(=O)(=O)NCCCCNC(=O)Cc4c(C)n(COc5ccc(Cl)cc5)c5ccc(OC)cc45)c(S)c3)c3ccc(=[N+](CC)CC)cc-3oc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 7/20 0.43
SLC6A2 P23975 4/20 0.43
SLC6A3 Q01959 4/20 0.43
CHRM1 P11229 2/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA4 P22748 2/20 0.38
CA9 Q16790 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
PPARG P37231 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
APLNR P35414 1/20 0.38
PTGS2 P35354 4/20 0.38
PTGS1 P23219 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL861715 0.86 PTGS2 (0.51) CA12CA1CA2CA4CA9
SCHEMBL860859 0.81 PTGS2 (0.47) SLC6A4SLC6A2SLC6A3CA12CA1
SCHEMBL13287108 0.81 PTGS2 (0.51) SLC6A4SLC6A2SLC6A3CA12CA1
SCHEMBL861082 0.79 PTGS2 (0.51) SLC6A4SLC6A2SLC6A3CHRM1CA12
SCHEMBL860893 0.77 CA12 (0.48) SLC6A4SLC6A2SLC6A3CHRM1CA12
SCHEMBL14351097 0.75 SLC6A4 (0.46) SLC6A4SLC6A2SLC6A3CHRM1CA12
SCHEMBL10148191 0.74 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3CHRM1APLNR
SCHEMBL16181479 0.72 PTGS2 (0.51) CA12CA1CA2CA4CA9
SCHEMBL16181481 0.68 CA12 (0.48) CA12CA1CA2CA4CA9
SCHEMBL10147685 0.68 CA12 (0.52) CA12CA1CA2CA4CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143302-B2 Methods and compositions for diagnostic and therapeutic targeting of COX-2 VANDERBILT UNIVERSITY (US) 2012-03-27 US disclosed
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 VANDERBILT UNIVERSITY (US) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 PTGS2, PTGES2, PTGER2 SLC6A4 3021/4885SLC6A2 2161/4885SLC6A3 3387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.